tert-butyl 4-((2,2-dimethoxyethyl)amino)piperidin-1-carboxylate | 701299-38-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-((2,2-dimethoxyethyl)amino)piperidin-1-carboxylate
• 英文别名: tert-butyl 4-(2,2-dimethoxyethylamino)piperidine-1-carboxylate
• CAS: 701299-38-9
• 化学式: C₁₄H₂₈N₂O₄
• 分子量: 288.387
• InChiKey: UEXIKULFPYHJKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  60
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((2,2-dimethoxyethyl)amino)piperidin-1-carboxylate 在 甲烷磺酸 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 19.0h， 生成 1-(6-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)-1,5-naphthyridin-4-yl)-3-(piperidin-4-yl)-1,3-dihydro-2H-imidazol-2-one
  参考文献：
  名称：

  EP3882247

  摘要：

  公开号：
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 、 氨基乙醛缩二甲醇 在 三乙酰氧基硼氢化钠 、 盐酸 、 碳酸氢钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 22.0h， 以74%的产率得到tert-butyl 4-((2,2-dimethoxyethyl)amino)piperidin-1-carboxylate
  参考文献：
  名称：

  CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS

  摘要：

  本发明包括受约束的双环和三环CGRP受体拮抗剂，识别它们的方法，包含它们的药物组合物，以及它们在治疗偏头痛和其他头痛、神经源性血管扩张、神经性炎症、热损伤、循环性休克、与更年期相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺病（COPD））中的用途，以及其他可以通过CGRP受体拮抗剂治疗的疾病。

  公开号：

  US20070259851A1

文献信息

• Imidazole derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070004736A1

  公开（公告）日：2007-01-04

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O) 2 — or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z 1 and Z 3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z 2 represents —N(R 1 )—, —O—, —S(O)—, —S(O) 2 —, —CO—, —CH(R 1 )— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R 1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，用作治疗血栓的药物，其化学式表示为(I)式：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价直链烃基，X代表可选取代的二价烃基，Y代表-CO-、-S(O)-、-S(O)2-或键，环A代表可选取代的吡咯烷环、可选取代的哌啶环或可选取代的过氢杂环己烷环，Z1和Z3独立地代表键或可选取代的二价直链烃基，Z2代表-N(R1)-、-O-、-S(O)-、-S(O)2-、-CO-、-CH(R1)-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所具有的取代基可以与R1一起形成可选取代的环，a代表0、1或2。
• Constrained compounds as CGRP-receptor antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US07470680B2

  公开（公告）日：2008-12-30

  The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  本发明涵盖了受限制的双环和三环CGRP受体拮抗剂，其鉴定方法，包含它们的制药组合物，以及在治疗偏头痛和其他头痛，神经性血管扩张，神经性炎症，热损伤，循环休克，与绝经期相关的潮红，气道炎症性疾病（如哮喘和慢性阻塞性肺疾病（COPD））以及其他可以通过CGRP受体拮抗剂治疗的疾病的治疗方法。
• IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE
  申请人：KUBO Keiji

  公开号：US20110009389A1

  公开（公告）日：2011-01-13

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents —CO—, —S(O)—, —S(O) 2 — or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z 1 and Z 3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z 2 represents —N(R 1 )—, —O—, —S(O)—, —S(O) 2 —, —CO—, —CH(R 1 )— or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R 1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，可用作治疗血栓的药物，其化学式表示为（I）：其中R代表可选取代的环烃基或可选取代的杂环基，W代表键或可选取代的二价线性烃基，X代表可选取代的二价烃基，Y代表-CO-，-S（O）-，-S（O）2-或键，环A代表可选取代的吡咯烷环，可选取代的哌啶环或可选取代的过氢化脂肪环，Z1和Z3独立地代表键或可选取代的二价线性烃基，Z2代表-N（R1）-，-O-，-S（O）-，-S（O）2-，-CO-，-CH（R1）-或键，环B代表可选取代的咪唑环，其中可选取代的咪唑环所代表的取代基可以与R1一起形成可选取代的环，a代表0，1或2。
• IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1564213A1

  公开（公告）日：2005-08-17

  There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, -S(O)-, -S(O)2- or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z1 and Z3 independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z2 represents -N(R1)-, -O-, - S(O)-, -S(O)2-, -CO-, -CH(R1)- or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R1 to form an optionally substituted ring, and a represents 0, 1 or 2.

  提供了一种咪唑衍生物，可用作血栓治疗剂，其由式(I)表示： 其中 R 代表任选取代的环状烃基或任选取代的杂环基，W 代表键或任选取代的二价线性烃基，X 代表任选取代的二价烃基，Y 代表 -CO-、-S(O)-、-S(O)2- 或键，环 A 代表任选取代的吡咯烷环、任选取代的哌啶环或任选取代的全氢氮杂卓环、Z1 和 Z3 独立地代表键或任选取代的二价线性烃基，Z2 代表-N(R1)-、-O-、-S(O)-、-S(O)2-、-CO-、-CH(R1)- 或键，环 B 代表任选取代的咪唑环，其中环 B 所代表的任选取代的咪唑环可能具有的取代基可与 R1 一起形成任选取代的环，a 代表 0、1 或 2。
• SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR
  申请人：Shanghai Ennovabio Pharmaceuticals Co., Ltd.

  公开号：EP3882247A1

  公开（公告）日：2021-09-22

  Provided are a preparation and applications of a six-membered fused with six-membered heterocyclic compound, specifically, provided in the present invention is a compound as represented by formula I as follows, where the definitions of the groups are as described in the description. The compound has TRK kinase inhibiting activity and can serve as a pharmaceutical composition for treating TRK dysfunction-related diseases.

  本发明提供了一种六元融合六元杂环化合物的制备方法及应用，具体而言，本发明提供了如下式I所代表的化合物，其中基团的定义如说明书所述。该化合物具有TRK激酶抑制活性，可作为治疗TRK功能障碍相关疾病的药物组合物。